Resell, M., Rabben, H.-L., Sharma, A., Hagen, L., Hoang, L., Skogaker, N. T., Aarvik, A., Bjåstad, E. K., Svensson, M. K., Amrutkar, M., Verbeke, C. S., Batra, S. K., Qvigstad, G., Wang, T. C., Rustgi, A., Chen, D., & Zhao, C.-M. (2025). Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Scientific Data, 12(1). https://doi.org/10.1038/s41597-025-04522-x

Patel, S. H., Colby, S., Sohal, D., Guthrie, K. A., Kachnic, L. A., Chiorean, E. G., Lowy, A. M., Rocha, F. G., Hochster, H. S., Philip, P. A., & Ahmad, S. A. (2025). Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. Cancer, 131(4). Portico. https://doi.org/10.1002/cncr.35759

Nishiwaki, N., Sugiura, K., Suzuki, K., Li, A. L., Contreras, C. T., Efe, G., Shin, A. E., Sadeghian, D., Zhao, J., Maitra, A., Pitarresi, J. R., Sims, P. A., Chandwani, R., & Rustgi, A. K. (2024). PRRX1 has functional roles in pancreatic acinar to ductal metaplasia and carcinogenesis. Cellular and Molecular Gastroenterology and Hepatology, 101442. https://doi.org/10.1016/j.jcmgh.2024.101442

Su, S. H., Mitani, Y., Li, T., Sachdeva, U., Flashner, S., Klein-Szanto, A., Dunbar, K. J., Abrams, J., Nakagawa, H., & Gabre, J. (2024). Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State. Biomolecules, 14(9), 1195. https://doi.org/10.3390/biom14091195

Connelly, C. F., Towne, W. S., Desai, N., Smithgall, M. C., Cimic, A., & Baskota, S. U. (2024). Cytologic testing for mismatch repair deficiency/microsatellite instability and NTRK gene fusion is not routinely indicated in primary pancreaticobiliary carcinoma cell block material. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2024.08.130

Saeki, K., Wood, I. S., Wang, W. C. K., Patil, S., Sun, Y., Schaeffer, D. F., Su, G. H., & Kopp, J. L. (2024). Acvr1b Loss Increases Formation of Pancreatic Precancerous Lesions From Acinar and Ductal Cells of Origin. Cellular and Molecular Gastroenterology and Hepatology, 18(5), 101387. https://doi.org/10.1016/j.jcmgh.2024.101387

Frank, J. S., Thomas, A. S., & Kluger, M. D. (2024). The role of CT imaging in proposed algorithm for managing post-operative hemorrhage after pancreaticoduodenectomy: case series. Surgery Case Reports, 3, 100042. https://doi.org/10.1016/j.sycrs.2024.100042

Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D., Lenz, H. J., Shields, A. F., Nabhan, C., El-Deiry, W., Seeber, A., Chiu, V., Hwang, J., & Lou, E. (2024). Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Gastrointestinal Oncology, 4, 100042. https://doi.org/10.1016/j.esmogo.2024.100042

Karloski, E., Dudley, B., Diergaarde, B., Blanco, A., Everett, J. N., Levinson, E., Rangarajan, T., Stanich, P. P., Childers, K., Brown, S., Drogan, C., Cavestro, G. M., Gordon, K., Singh, A., Simeone, D. M., Reich, H., Kastrinos, F., Zakalik, D., Hampel, H., … Brand, R. E. (2024). The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Cancer. Portico. https://doi.org/10.1002/cncr.35383

Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., Drizyte-Miller, K., Menard, M., Dilly, J., Sastra, S. A., Palermo, C. F., Hasselluhn, M. C., Decker-Farrell, A. R., Chang, S., Jiang, L., … Olive, K. P. (2024). Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature, 629(8013), 927–936. https://doi.org/10.1038/s41586-024-07379-z

Zogopoulos, G., Haimi, I., Sanoba, S. A., Everett, J. N., Wang, Y., Katona, B. W., Farrell, J. J., Grossberg, A. J., Paiella, S., Klute, K. A., Bi, Y., Wallace, M. B., Kwon, R. S., Stoffel, E. M., Wadlow, R. C., Sussman, D. A., Merchant, N. B., Permuth, J. B., Golan, T., … __. (2024). The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Journal of the National Comprehensive Cancer Network, 22(3), 158–166. https://doi.org/10.6004/jnccn.2023.7097

Saqi, A., Nishino, M., Saieg, M., Ly, A., & Lott Limbach, A. (2024). Doing more with less: integrating small biopsies in cytology practice. Journal of the American Society of Cytopathology, 13(4), 233–243. https://doi.org/10.1016/j.jasc.2024.03.005

Ross, A. B., Gorhe, D., Kim, J. K., Hodapp, S., DeVine, L., Chan, K. M., Chio, I. I. C., Jovanovic, M., & Ayres Pereira, M. (2024). Systematic analysis of proteome turnover in an organoid model of pancreatic cancer by dSILO. Cell Reports Methods, 4(5), 100760. https://doi.org/10.1016/j.crmeth.2024.100760

Ben-Ami, R., Wang, Q.-L., Zhang, J., Supplee, J. G., Fahrmann, J. F., Lehmann-Werman, R., Brais, L. K., Nowak, J., Yuan, C., Loftus, M., Babic, A., Irajizad, E., Davidi, T., Zick, A., Hubert, A., Neiman, D., Piyanzin, S., Gal-Rosenberg, O., Horn, A., … Wolpin, B. M. (2023). Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut, gutjnl-2023-331074. https://doi.org/10.1136/gutjnl-2023-331074

Vujasinovic, M., Elbe, P., Ekheden, I., Wang, Q.-L., Thuresson, M., Roelstraete, B., Ghazi, S., Löhr, J.-M., & Ludvigsson, J. F. (2024). Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms: a nationwide cohort study. Scandinavian Journal of Gastroenterology, 59(5), 600–607. https://doi.org/10.1080/00365521.2024.2310162

Tchouta, L. N., & Schrope, B. A. (2023). Evolving Technique for Puestow-Type Procedure for Chronic Pancreatitis: The Combined Roux-en-Y Proximal End-to-Side and Distal Longitudinal Pancreatojejunostomy. American Journal of Case Reports, 25. https://doi.org/10.12659/ajcr.942066

Elmi, N., McEvoy, D., McInnes, M. D. F., Alabousi, M., Hecht, E. M., Luk, L., Asghar, S., Jajodia, A., de Carvalho, T. L., Warnica, W. J., Zha, N., Ullah, S., & van der Pol, C. B. (2023). Percentage of Pancreatic Cysts on MRI With a Pancreatic Carcinoma: Systematic Review and Meta‐Analysis. Journal of Magnetic Resonance Imaging. Portico. https://doi.org/10.1002/jmri.29168

Decker-Farrell, A. R., Ma, A., Li, F., Muir, A., & Olive, K. P. (2023). Generation and ex vivo culture of murine and human pancreatic ductal adenocarcinoma tissue slice explants. STAR Protocols, 4(4), 102711. https://doi.org/10.1016/j.xpro.2023.102711

Park, J., Lim, F., Prest, M., Ferris, J. S., Aziz, Z., Agyekum, A., Wagner, S., Gulati, R., & Hur, C. (2023). Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-46751-3

Rajbhandari, N., Hamilton, M., Quintero, C. M., Ferguson, L. P., Fox, R., Schürch, C. M., Wang, J., Nakamura, M., Lytle, N. K., McDermott, M., Diaz, E., Pettit, H., Kritzik, M., Han, H., Cridebring, D., Wen, K. W., Tsai, S., Goggins, M. G., Lowy, A. M., … Reya, T. (2023). Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Cancer Cell, 41(11), 1989-2005.e9. https://doi.org/10.1016/j.ccell.2023.09.008

Lee, E., O’Keefe, S., Leong, A., Park, H.-R., Varadarajan, J., Chowdhury, S., Hiner, S., Kim, S., Shiva, A., Friedman, R. A., Remotti, H., Fojo, T., Yang, H. W., Thurston, G., & Kim, M. (2023). Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment. Journal of Clinical Investigation, 133(20). https://doi.org/10.1172/jci167994

Shah, I., Yakah, W., Ahmed, A., Freedman, S. D., Jiang, Z. G., & Sheth, S. G. (2023). GlycA: Evaluation of a New Biomarker of Acute Pancreatitis. Biomolecules, 13(10), 1530. https://doi.org/10.3390/biom13101530

El Menabawey, T., Mulay, A., Graham, D., Phillpotts, S., Sethi, A., & Webster, G. J. (2023). Predictors of success of conventional ERCP for bile duct stones and need for single-operator cholangioscopy. Endoscopy International Open, 11(10), E943–E951. CLOCKSS. https://doi.org/10.1055/a-2164-8557

Connelly, C., Towne, W., Smithgall, M., Cimic, A., & Baskota, S. U. (2023). Pan-TRK Immunostain for Primary Pancreaticobiliary Carcinomas in Cell Block: A Detailed Study of 233 Cases. Journal of the American Society of Cytopathology, 12(5), S47. https://doi.org/10.1016/j.jasc.2023.07.083

Irajizad, E., Kenney, A., Tang, T., Vykoukal, J., Wu, R., Murage, E., Dennison, J. B., Sans, M., Long, J. P., Loftus, M., Chabot, J. A., Kluger, M. D., Kastrinos, F., Brais, L., Babic, A., Jajoo, K., Lee, L. S., Clancy, T. E., Ng, K., … Fahrmann, J. F. (2023). A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Reports Medicine, 4(9), 101194. https://doi.org/10.1016/j.xcrm.2023.101194

Manji, G. A., Labadie, B. W., Lee, S. M., Pellicciotta, I., Ge, L., Sta Ana, S., Sender, N., Ross, I., Wong, W., & Raufi, A. G. (2023). MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies. JCO Global Oncology, 9(Supplement_1), 45–45. https://doi.org/10.1200/go.2023.9.supplement_1.45

Ko, A. H., Kim, K.-P., Siveke, J. T., Lopez, C. D., Lacy, J., O’Reilly, E. M., Macarulla, T., Manji, G. A., Lee, J., Ajani, J., Alsina Maqueda, M., Rha, S.-Y., Lau, J., Al-Sakaff, N., Allen, S., Lu, D., Shemesh, C. S., Gan, X., Cha, E., & Oh, D.-Y. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist, 28(6), 553-e472. https://doi.org/10.1093/oncolo/oyad022

Perez, K., Chiarella, A. M., Cleary, J. M., Horick, N., Weekes, C., Abrams, T., Blaszkowsky, L., Enzinger, P., Giannakis, M., Goyal, L., Meyerhardt, J. A., Rubinson, D., Yurgelun, M. B., Goessling, W., Giantonio, B. J., Brais, L., Germon, V., Stonely, D., Raghavan, S., … Wolpin, B. M. (2023). Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The Oncologist, 28(5), 425–432. https://doi.org/10.1093/oncolo/oyad002

Dercle, L., Fronheiser, M., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., Zhao, B., & Leung, D. K. (2023). Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. Journal of Thoracic Oncology, 18(5), 587–598. https://doi.org/10.1016/j.jtho.2022.12.019

Fulop, D. J., Zylberberg, H. M., Wu, Y. L., Aronson, A., Labiner, A. J., Wisnivesky, J., Cohen, D. J., Sigel, K. M., & Lucas, A. L. (2023). Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA Network Open, 6(3), e234254. https://doi.org/10.1001/jamanetworkopen.2023.4254

Yeh, C., Zhou, M., Sigel, K., Jameson, G., White, R., Safyan, R., Saenger, Y., Hecht, E., Chabot, J., Schreibman, S., Juzyna, B., Ychou, M., Conroy, T., Fojo, T., Manji, G. A., Von Hoff, D., & Bates, S. E. (2022). Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 28(2), 139–148. https://doi.org/10.1093/oncolo/oyac217

Parejo-Alonso, B., Royo-García, A., Espiau-Romera, P., Courtois, S., Curiel-García, Á., Zagorac, S., Villaoslada, I., Olive, K. P., Heeschen, C., & Sancho, P. (2023). Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Biomedicine & Pharmacotherapy, 158, 114162. https://doi.org/10.1016/j.biopha.2022.114162

Park, J., Artin, M. G., Lee, K. E., May, B. L., Park, M., Hur, C., & Tatonetti, N. P. (2023). Structured deep embedding model to generate composite clinical indices from electronic health records for early detection of pancreatic cancer. Patterns, 4(1), 100636. https://doi.org/10.1016/j.patter.2022.100636

Gartrell, R. D., Enzler, T., Kim, P. S., Fullerton, B. T., Fazlollahi, L., Chen, A. X., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., Wang, S., Oh, E. J., Guo, X. V., Chiuzan, C., Manji, G. A., Bates, S. E., Chabot, J., Schrope, B., Kluger, M., … Saenger, Y. M. (2022). Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2066767

Saeki, K., Qiu, W., Friedman, R. A., Pan, S., Lu, J., Ichimiya, S., Chio, I. I. C., Shawber, C. J., Kitajewski, J., Hu, J., & Su, G. H. (2022). Inactivation ofNotch4Attenuated Pancreatic Tumorigenesis in Mice. Cancer Research Communications, 2(12), 1601–1616. https://doi.org/10.1158/2767-9764.crc-22-0106

Yu, J., & Pajvani, U. B. (2022). Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. Medical Review, 2(6), 544–546. https://doi.org/10.1515/mr-2022-0043

Cordo’, V., Meijer, M. T., Hagelaar, R., de Goeij-de Haas, R. R., Poort, V. M., Henneman, A. A., Piersma, S. R., Pham, T. V., Oshima, K., Ferrando, A. A., Zaman, G. J. R., Jimenez, C. R., & Meijerink, J. P. P. (2022). Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-28682-1

Curiel-Garcia, A., Decker-Farrell, A. R., Sastra, S. A., & Olive, K. P. (2022). Generation of orthotopic patient-derived xenograft models for pancreatic cancer using tumor slices. STAR Protocols, 3(4), 101899. https://doi.org/10.1016/j.xpro.2022.101899

Bauer, T., Cho, B. C., Heist, R., Bazhenova, L., Werner, T., Goel, S., Kim, D.-W., Adkins, D., Carvajal, R. D., Alva, A., Eaton, K., Wang, J., Liu, Y., Yan, X., Christensen, J., Neuteboom, S., Chao, R., & Pant, S. (2022). First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Investigational New Drugs, 40(5), 990–1000. https://doi.org/10.1007/s10637-022-01274-y

Perdigoto, A. L., Deng, S., Du, K. C., Kuchroo, M., Burkhardt, D. B., Tong, A., Israel, G., Robert, M. E., Weisberg, S. P., Kirkiles-Smith, N., Stamatouli, A. M., Kluger, H. M., Quandt, Z., Young, A., Yang, M.-L., Mamula, M. J., Pober, J. S., Anderson, M. S., Krishnaswamy, S., & Herold, K. C. (2022). Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes. JCI Insight, 7(17). https://doi.org/10.1172/jci.insight.156330

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., Kastrinos, F., Manji, G. A., Kong, C. Y., & Hur, C. (2022). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 5(9). Portico. https://doi.org/10.1002/cnr2.1565

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Scales, M. K., Velez-Delgado, A., Steele, N. G., Schrader, H. E., Stabnick, A. M., Yan, W., Mercado Soto, N. M., Nwosu, Z. C., Johnson, C., Zhang, Y., Salas-Escabillas, D. J., Menjivar, R. E., Maurer, H. C., Crawford, H. C., Bednar, F., Olive, K. P., Pasca di Magliano, M., & Allen, B. L. (2022). Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. PLOS Genetics, 18(7), e1010315. https://doi.org/10.1371/journal.pgen.1010315

Park, J., Artin, M. G., Lee, K. E., Pumpalova, Y. S., Ingram, M. A., May, B. L., Park, M., Hur, C., & Tatonetti, N. P. (2022). Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. Journal of Biomedical Informatics, 131, 104095. https://doi.org/10.1016/j.jbi.2022.104095

Caplan, L. R., Vavinskaya, V., Gelikman, D. G., Jyotsana, N., Trinh, V. Q., Olive, K. P., Tan, M. C. B., & DelGiorno, K. E. (2022). Enteroendocrine Cell Formation Is an Early Event in Pancreatic Tumorigenesis. Frontiers in Physiology, 13. https://doi.org/10.3389/fphys.2022.865452

Rustgi, S. D., Zylberberg, H. M., Amin, S., Aronson, A., Nagula, S., DiMaio, C. J., Kumta, N. A., & Lucas, A. L. (2022). Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016. Endoscopy International Open, 10(01), E19–E29. CLOCKSS. https://doi.org/10.1055/a-1608-0856

Shou, A., Thomas, A., Kwon, W., & Kluger, M. (2022). Pancreatic Cancer After Solid-Organ Transplantation: A Descriptive Series. HPB, 24, S394. https://doi.org/10.1016/j.hpb.2022.05.836

Thomas, A., Huang, Y., Schrope, B., Sugahara, K., Chabot, J., Wright, J., & Kluger, M. (2022). Prevalence of Diabetes and Pancreatic Insufficiency Plateau within Six Months of Pancreatectomy. HPB, 24, S66–S67. https://doi.org/10.1016/j.hpb.2022.05.123

Thomas, A., Kwon, W., Tehranifar, P., Sugahara, K., Schrope, B., Chabot, J., Genkinger, J., & Kluger, M. (2022). Barriers to Standard of Care in the United States: Trends in the Treatment of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. HPB, 24, S36. https://doi.org/10.1016/j.hpb.2022.05.071